Back

Increasing use of NOAC and antiplatelet combination therapy in atrial fibrillation following myocardial infarction or percutaneous coronary intervention

28 August 2017 (09:15 - 09:24)
Organised by:
Congress Presentation Part of: Drug treatment in patients with arrhythmia Antiarrhythmic drugs ESC Premium Access ESC Congress 2017

About the speaker

Photo
Ms Caroline Sindet-Pedersen

Gentofte Hospital - Copenhagen University Hospital, Hellerup (Denmark)

7 More presentations in this session

Presentation thumbnail
Association between sociodemographic factors and choice of Direct Oral Anticoagulants versus warfarin in atrial fibrillation: A population based cross-sectional study using Swedish Registers
Mr G. Brobert (Solna, SE)
Abstract Slides Video
Presentation thumbnail
Favorable effect of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with liver cirrhosis
Doctor H. Yu (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Non-vitamin K antagonist oral anticoagulants in comparison to phenprocoumon in a real-word setting of atrial fibrillation: an analysis of a large german health claims dataset
Mr C. Hohmann (Cologne, DE)
Abstract Slides Video
Presentation thumbnail
Dabigatran-induced esophagitis after radiofrequency catheter ablation
Doctor Y. Ito (Tsukuba, JP)
Abstract
Presentation thumbnail
Epicardial application of amiodarone-releasing hydrogel: experimental study
Professor O. Bockeria (Moscow, RU)
Abstract Slides Video

Access the full session

Session thumbnail
Drug treatment in patients with arrhythmia

The Event

Event poster

ESC Congress 2017

28 August 2017 09:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources